Literature DB >> 24028270

A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver.

Yunus Taşçi1, Erol Aksoy, Halit Eren Taşkın, Shamil Aliyev, Halle Moore, Orhan Ağcaoğlu, Onur Birsen, Allan Siperstein, Eren Berber.   

Abstract

OBJECTIVES: There is controversy about the roles of locoregional therapies in patients with liver metastases from breast cancer (LMBC). The aim of this study was to analyse survival after laparoscopic radiofrequency ablation (RFA) of LMBC and to compare this with survival in patients receiving systemic therapy (ST) alone.
METHODS: During 1996-2011, 24 patients who had failed to respond or had shown an incomplete response to ST underwent laparoscopic RFA for LMBC. Outcomes in these patients were compared with those in 32 patients with LMBC matched by tumour size and number, but treated with ST alone. Clinical parameters and overall survival were compared using t-tests, chi-squared tests and Kaplan-Meier analysis.
RESULTS: The groups were similar in hormone receptor status and chemotherapy exposure. In the laparoscopic RFA and ST groups, respectively, the mean ± standard deviation size of the dominant liver tumour and the number of tumours per patient were 3.7 ± 0.4 cm and 2.4 ± 0.4 cm, and 2.6 ± 0.4 tumours and 3.3 ± 0.4 tumours, respectively. These differences were not significant. At a median follow-up of 20 months in the laparoscopic RFA group, 42% of patients were found to have developed local liver recurrence, 63% had developed new liver disease and 38% had developed extrahepatic disease. Overall survival after the diagnosis of liver metastasis was 47 months in the laparoscopic RFA group and 9 months in the ST-only group (P = 0.0001). Five-year survival after the diagnosis of liver metastasis was 29% in the RFA group and 0% in the ST-only group.
CONCLUSIONS: This is the first study to compare outcomes in RFA and ST, respectively, in LMBC. The results show that survival after laparoscopic RFA plus ST is better than that after ST alone.
© 2013 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24028270      PMCID: PMC3791118          DOI: 10.1111/hpb.12133

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  28 in total

1.  Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.

Authors:  A Onyenadum; H Gogas; P Kosmidis; G Aravantinos; D Bafaloukos; H Bacoyiannis; C Markopoulos; A Koutras; E Tzorakoelefterakis; T Makatsoris; G Fountzilas; H P Kalofonos
Journal:  J Chemother       Date:  2006-04       Impact factor: 1.714

2.  Ultrasound-guided thermal radiofrequency ablation (RFA) as an adjunct to systemic chemotherapy for breast cancer liver metastases.

Authors:  G Carrafiello; F Fontana; E Cotta; M Petullà; L Brunese; M Mangini; C Fugazzola
Journal:  Radiol Med       Date:  2011-06-04       Impact factor: 3.469

Review 3.  Liver resection and local ablation of breast cancer liver metastases--a systematic review.

Authors:  M Bergenfeldt; B V Jensen; B Skjoldbye; D Nielsen
Journal:  Eur J Surg Oncol       Date:  2011-05-24       Impact factor: 4.424

4.  Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up.

Authors:  Hizir Yakup Akyildiz; Jamie Mitchell; Mira Milas; Allan Siperstein; Eren Berber
Journal:  Surgery       Date:  2010-12       Impact factor: 3.982

5.  Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients.

Authors:  T Livraghi; S N Goldberg; L Solbiati; F Meloni; T Ierace; G S Gazelle
Journal:  Radiology       Date:  2001-07       Impact factor: 11.105

6.  Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients.

Authors:  Gowthaman Gunabushanam; Sanjay Sharma; Sanjay Thulkar; Deep N Srivastava; Goura Kishor Rath; Pramod Kumar Julka; Sushma Bhatnagar
Journal:  J Vasc Interv Radiol       Date:  2007-01       Impact factor: 3.464

Review 7.  An attempt to clarify indications for hepatectomy for liver metastases from breast cancer.

Authors:  Dominique Elias; Franck Maisonnette; Michel Druet-Cabanac; Jean Francois Ouellet; Jean Marc Guinebretiere; Marc Spielmann; Suzette Delaloge
Journal:  Am J Surg       Date:  2003-02       Impact factor: 2.565

8.  Radiofrequency ablation in the management of liver metastases from breast cancer.

Authors:  C T Sofocleous; R G Nascimento; M Gonen; M Theodoulou; A M Covey; L A Brody; S M Solomon; R Thornton; Y Fong; G I Getrajdman; K T Brown
Journal:  AJR Am J Roentgenol       Date:  2007-10       Impact factor: 3.959

9.  Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

Authors:  Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

10.  Liver metastases from breast cancer. Results of surgical resection.

Authors:  Massimo Carlini; Maria Teresa Lonardo; Fabio Carboni; Marija Petric; Carlo Vitucci; Roberto Santoro; Pasquale Lepiane; Giuseppe M Ettorre; Eugenio Santoro
Journal:  Hepatogastroenterology       Date:  2002 Nov-Dec
View more
  8 in total

1.  Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer.

Authors:  Iben Kümler; Vibeke Kirk Parner; Malgorzata K Tuxen; Bjørn Skjoldbye; Magnus Bergenfeldt; Knud Mejer Nelausen; Dorte Lisbet Nielsen
Journal:  Radiol Med       Date:  2015-01-09       Impact factor: 3.469

Review 2.  Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?

Authors:  Simona Di Lascio; Olivia Pagani
Journal:  Breast Care (Basel)       Date:  2014-02       Impact factor: 2.860

3.  Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients.

Authors:  Eran Sadot; Ser Yee Lee; Constantinos T Sofocleous; Stephen B Solomon; Mithat Gönen; T Peter Kingham; Peter J Allen; Ronald P DeMatteo; William R Jarnagin; Clifford A Hudis; Michael I D'Angelica
Journal:  Ann Surg       Date:  2016-07       Impact factor: 12.969

4.  Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study).

Authors:  Max Seidensticker; Benjamin Garlipp; Sophia Scholz; Konrad Mohnike; Felix Popp; Ingo Steffen; Ricarda Seidensticker; Patrick Stübs; Maciej Pech; Maciej PowerskI; Peter Hass; Serban-Dan Costa; Holger Amthauer; Christiane Bruns; Jens Ricke
Journal:  BMC Cancer       Date:  2015-07-14       Impact factor: 4.430

5.  Hepatectomy, RFA, and Other Liver Directed Therapies for Treatment of Breast Cancer Liver Metastasis: A Systematic Review.

Authors:  Kevin Rivera; Dhiresh Rohan Jeyarajah; Kimberly Washington
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

6.  Clinical Effectiveness of Hypofractionated Proton Beam Therapy for Liver Metastasis From Breast Cancer.

Authors:  Tae Hyun Kim; Keun Seok Lee; Sung Hoon Sim; Yeon-Joo Kim; Dae Yong Kim; Heejung Chae; Eun-Gyeong Lee; Jai Hong Han; So Youn Jung; Seeyoun Lee; Han Sung Kang; Eun Sook Lee
Journal:  Front Oncol       Date:  2021-11-03       Impact factor: 6.244

7.  The global status of research in breast cancer liver metastasis: a bibliometric and visualized analysis.

Authors:  Yanlong Shi; Wei Wei; Li Li; Qian Wei; Fei Jiang; Guozhi Xia; Hongzhu Yu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  Predictive Nomogram of Subsequent Liver Metastasis After Mastectomy or Breast-Conserving Surgery in Patients With Nonmetastatic Breast Cancer.

Authors:  Anli Yang; Weikai Xiao; Shaoquan Zheng; Yanan Kong; Yutian Zou; Mingyue Li; Feng Ye; Xiaoming Xie
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.